-
1
-
-
67349142163
-
A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size
-
Sakuma Y, Okamoto N, Saito H, et al. A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size. Lung Cancer 2009;65:85-90.
-
(2009)
Lung Cancer
, vol.65
, pp. 85-90
-
-
Sakuma, Y.1
Okamoto, N.2
Saito, H.3
-
2
-
-
0028057613
-
Disruption of epithelial cell-matrix interactions induces apoptosis
-
Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626. (Pubitemid 24064472)
-
(1994)
Journal of Cell Biology
, vol.124
, Issue.4
, pp. 619-626
-
-
Frisch, S.M.1
Francis, H.2
-
3
-
-
10944223361
-
Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis
-
DOI 10.1038/sj.onc.1208091
-
Wei L, Yang Y, Zhang X, et al. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 2004;23:9052-9061. (Pubitemid 40013072)
-
(2004)
Oncogene
, vol.23
, Issue.56
, pp. 9052-9061
-
-
Wei, L.1
Yang, Y.2
Zhang, X.3
Yu, Q.4
-
4
-
-
35649025769
-
CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma
-
DOI 10.1128/MCB.01246-07
-
Uekita T, Jia L, Narisawa-Saito M, et al. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007;27:7649-7660. (Pubitemid 350033670)
-
(2007)
Molecular and Cellular Biology
, vol.27
, Issue.21
, pp. 7649-7660
-
-
Uekita, T.1
Jia, L.2
Narisawa-Saito, M.3
Yokota, J.4
Kiyono, T.5
Sakai, R.6
-
5
-
-
77949863504
-
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src
-
Sakuma Y, Takeuchi T, Nakamura Y, et al. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. J Pathol 2010;220:574-585.
-
(2010)
J Pathol
, vol.220
, pp. 574-585
-
-
Sakuma, Y.1
Takeuchi, T.2
Nakamura, Y.3
-
6
-
-
44849112219
-
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
-
Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
-
(2008)
Cancer Res
, vol.68
, pp. 3421-3428
-
-
Tse, C.1
Shoemaker, A.R.2
Adickes, J.3
-
7
-
-
65849378710
-
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
-
Cragg MS, Harris C, Strasser A, et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009;9:321-326.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 321-326
-
-
Cragg, M.S.1
Harris, C.2
Strasser, A.3
-
8
-
-
79551599947
-
ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis
-
Sakuma Y, Tsunezumi J, Nakamura Y, et al. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep 2011;25:661-667.
-
(2011)
Oncol Rep
, vol.25
, pp. 661-667
-
-
Sakuma, Y.1
Tsunezumi, J.2
Nakamura, Y.3
-
9
-
-
35648953299
-
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
-
Cragg MS, Kuroda J, Puthalakath H, et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681-1689.
-
(2007)
PLoS Med
, vol.4
, pp. 1681-1689
-
-
Cragg, M.S.1
Kuroda, J.2
Puthalakath, H.3
-
10
-
-
35648965243
-
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas
-
Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas. PLoS Med 2007;4:e294.
-
(2007)
PLoS Med
, vol.4
-
-
Gong, Y.1
Somwar, R.2
Politi, K.3
-
11
-
-
33847323129
-
Epidermal growth factor receptor mutations in lung cancer
-
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 169-181
-
-
Sharma, S.V.1
Bell, D.W.2
Settleman, J.3
-
12
-
-
77958478674
-
Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer
-
Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 760-774
-
-
Pao, W.1
Chmielecki, J.2
-
13
-
-
77952105211
-
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
-
Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17: 427-442.
-
(2010)
Cancer Cell
, vol.17
, pp. 427-442
-
-
Zhang, B.1
Strauss, A.C.2
Chu, S.3
-
14
-
-
33745243692
-
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
-
DOI 10.1158/0008-5472.CAN-05-4620
-
Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66: 5542-5548. (Pubitemid 43927102)
-
(2006)
Cancer Research
, vol.66
, Issue.11
, pp. 5542-5548
-
-
Song, L.1
Morris, M.2
Bagui, T.3
Lee, F.Y.4
Jove, R.5
Haura, E.B.6
-
15
-
-
33847009160
-
Src-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines
-
DOI 10.2353/ajpath.2007.060706
-
Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-376. (Pubitemid 47339214)
-
(2007)
American Journal of Pathology
, vol.170
, Issue.1
, pp. 366-376
-
-
Zhang, J.1
Kalyankrishna, S.2
Wislez, M.3
Thilaganathan, N.4
Saigal, B.5
Wei, W.6
Ma, L.7
Wistuba, I.I.8
Johnson, F.M.9
Kurie, J.M.10
-
16
-
-
67349269541
-
The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancerassociated EGF receptor mutants
-
Chung BM, Dimri M, George M, et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancerassociated EGF receptor mutants. Oncogene 2009;28:1821-1832.
-
(2009)
Oncogene
, vol.28
, pp. 1821-1832
-
-
Chung, B.M.1
Dimri, M.2
George, M.3
-
17
-
-
72949092456
-
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
-
Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-1074.
-
(2009)
Nature
, vol.462
, pp. 1070-1074
-
-
Zhou, W.1
Ercan, D.2
Chen, L.3
-
18
-
-
0034024551
-
Poly(ADP-ribose) polymerase in DNA damage-response pathway: Implications for radiation oncology
-
DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4
-
Soldatenkov VA, Smulson M. Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. Int J Cancer 2000;90:59-67. (Pubitemid 30253030)
-
(2000)
International Journal of Cancer
, vol.90
, Issue.2
, pp. 59-67
-
-
Soldatenkov, V.A.1
Smulson, M.2
-
19
-
-
1542344542
-
Agarose Cell Block: Innovated Technique for the Processing of Urine Cytology for Electron Microscopy Examination
-
Mansy SS. Agarose cell block: innovated technique for the processing of urine cytology for electron microscopy examination. Ultrastruct Pathol 2004;28:15-21. (Pubitemid 38299720)
-
(2004)
Ultrastructural Pathology
, vol.28
, Issue.1
, pp. 15-21
-
-
Mansy, S.S.1
-
20
-
-
33748592818
-
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay
-
DOI 10.2353/jmoldx.2006.060030
-
Matsukuma S, Yoshihara M, Kasai F, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006;8:504-512. (Pubitemid 44377934)
-
(2006)
Journal of Molecular Diagnostics
, vol.8
, Issue.4
, pp. 504-512
-
-
Matsukuma, S.1
Yoshihara, M.2
Kasai, F.3
Kato, A.4
Yoshida, A.5
Akaike, M.6
Kobayashi, O.7
Nakayama, H.8
Sakuma, Y.9
Yoshida, T.10
Kameda, Y.11
Tsuchiya, E.12
Miyagi, Y.13
-
21
-
-
77957273623
-
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
-
Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010;107:15535-15540.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 15535-15540
-
-
Yao, Z.1
Fenoglio, S.2
Gao, D.C.3
-
22
-
-
77950809059
-
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
-
Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
-
(2010)
Cell
, vol.141
, pp. 69-80
-
-
Sharma, S.V.1
Lee, D.Y.2
Li, B.3
-
23
-
-
70349758510
-
Src kinases as therapeutic targets for cancer
-
Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-595.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 587-595
-
-
Kim, L.C.1
Song, L.2
Haura, E.B.3
-
24
-
-
77950491674
-
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
-
Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1387-1394.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1387-1394
-
-
Haura, E.B.1
Tanvetyanon, T.2
Chiappori, A.3
-
25
-
-
38949107292
-
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: Implications in targeting therapy
-
DOI 10.1038/sj.onc.1210684, PII 1210684
-
Fu YN, Yeh CL, Cheng HH, et al. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 2008;27:957-965. (Pubitemid 351225379)
-
(2008)
Oncogene
, vol.27
, Issue.7
, pp. 957-965
-
-
Fu, Y.-N.1
Yeh, C.-L.2
Cheng, H.H.-Y.3
Yang, C.-H.4
Tsai, S.-F.5
Huang, S.-F.6
Chen, Y.-R.7
-
26
-
-
72949119124
-
Integrins in cancer: Biological implications and therapeutic opportunities
-
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 9-22
-
-
Desgrosellier, J.S.1
Cheresh, D.A.2
-
27
-
-
79953740723
-
Malignant pleural effusion from lung adenocarcinoma treated by gefitinib
-
Kubo A, Koh Y, Kawaguchi T, et al. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. Intern Med 2011;50: 745-748.
-
(2011)
Intern Med
, vol.50
, pp. 745-748
-
-
Kubo, A.1
Koh, Y.2
Kawaguchi, T.3
-
28
-
-
77952502408
-
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth
-
Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583-594.
-
(2010)
Cell
, vol.141
, pp. 583-594
-
-
Roesch, A.1
Fukunaga-Kalabis, M.2
Schmidt, E.C.3
-
29
-
-
79959916680
-
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
-
Fan W, Tang Z, Yin L, et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 2011;71:4494-4505.
-
(2011)
Cancer Res
, vol.71
, pp. 4494-4505
-
-
Fan, W.1
Tang, Z.2
Yin, L.3
-
30
-
-
79961218347
-
Asymmetric cancer cell division regulated by AKT
-
Dey-Guha I, Wolfer A, Yeh AC, et al. Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci USA 2011;108:12845-12850.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 12845-12850
-
-
Dey-Guha, I.1
Wolfer, A.2
Yeh, A.C.3
-
31
-
-
34748840882
-
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
-
DOI 10.1158/1535-7163.MCT-06-0761
-
Edwards A, Li J, Atadja P, et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007;6:2515-2524. (Pubitemid 47480417)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.9
, pp. 2515-2524
-
-
Edwards, A.1
Li, J.2
Atadja, P.3
Bhalla, K.4
Haura, E.B.5
-
32
-
-
4644304383
-
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
-
DOI 10.1038/sj.onc.1207893
-
Burgess A, Ruefli A, Beamish H, et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004;23: 6693-6701. (Pubitemid 39280001)
-
(2004)
Oncogene
, vol.23
, Issue.40
, pp. 6693-6701
-
-
Burgess, A.1
Ruefli, A.2
Beamish, H.3
Warrener, R.4
Saunders, N.5
Johnstone, R.6
Gabrielli, B.7
|